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Outcomes among those who are ineligible for thrombolysis worse 
than for those who are eligible and receive thrombolytic agents (2,3). 
Thus, one would expect a mixed group of thrombolysis eligible and 
ineligible patients to be older, more likely to be male and to have a 
higher degree of comorbidity than a group of only thrombolysis eligible 
patients. To conclude that there was true selection bias in the 
recruitment of study participants, one needs to compare the charac- 
teristics of participants with those who were nonparticipants but met 
study criteria for randomization. Because Jha et al. do not have access 
to data that would allow this comparison, they cannot show true 
selection bias. Additionally, observational studies, such as this one, 
which attempt to show outcome differences, must adjust for case mix of 
the different patient groups. The authors duly note that outcome in 
acute myocardial infarction is highly dependent on a number of 
physiologic variables, uch as admission heart rate, blood pressure and 
Killip class. None of these data were available for nonparticipants. In 
the absence of these data, it is difficult to determine whether outcome 
differences occurred due to differences in treatment received or 
because of differences in unmeasured baseline characteristics. 
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Reply 
In part, Sada simply echoes a caveat hat we presented along with our 
findings, namely, that better characterization f patients would be 
important to explain observed outcome differences (l). We also agree 
that examination ofeligibility for thrombolysis inall participants would 
be the most rigorous way to pin down selection bias. That is where the 
agreement ends. 
Sada would have us believe that thrombolysis eligibility alone 
accounts for the observed ifferences between trial participants and 
nonparticipants. Ironically, one of the references (2) he cites to 
support his argument was actually ameticulous dissection of the extent 
of underutilization f thrombolysis, wherein the authors championed 
the importance of treating elderly patients and those presenting 6 to 
12 h from symptom onset. The second study cited by Sada was by 
Cragg et al. (3). It examined patients presenting to one center between 
1986 and 1988, stated that only 16% of the patients were treated with 
thrombolytics and cited a whole series of now-obsolete criteria as 
reasons for deeming patients ineligible for treatment. Among those 
criteria were age >76 years, presentation >4 h from symptom onset, 
any previous coronary artery, bypass urgery., angioplasty in the pre- 
ceding 2 weeks and left bundle branch block. We are puzzled as to why 
Sada cited this study; but having cited it, he might at least have got the 
authors' message right. Cragg et al. (3) directly challenged the age 
limits on enrollment in thrombolysis trials as likely to cost many lives 
and also wrote: "Apart from the significant age difference, why 
protocol-treated patients had such low-risk characteristics was unclear; 
the inclusion and exclusion criteria did not specifically preclude 
enrollment for patients with many of these high-risk characteristics." 
The evidence for underuse of thrombolytic therapy among elderly 
patients continues to roll in. The most recent study (4) in 11 European 
countries howed that up to 55% of patients with acute myocardial 
infarction were eligible for thrombolysis. However, compared with 
those >65 years old, the odds ratios for use of thrombolysis among 
eligible patients by age bracket were as follows: 65 to 74 years, 0.55 
(95% confidence interval [CI] 0.34 to 0.89); 75 to 84 years, 0.24 (95% 
CI 0.14 to 0.40); and >85 years, 0.04 (95% CI 0.02 to 0.10). 
As our article suggested (4), it seems plausible that arbitrary 
enrollment restrictions in early trials shaped the early perceptions of 
eligibility for thrombolysis, and these biases have continued to influ- 
ence patient selection in both newer trials and ordinary practice. The 
causes, effects and epiphenomena are hard to tease apart; and more 
studies are needed. However, what matters now is optimizing the use 
of thrombolysis around the world and ensuring that any new therapies 
for acute myocardial infarction are tested in a proper spectrum of low 
and high risk patients of all ages. 
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